ClinicalTrials.gg
CompletedNCT02261064Updated Oct 10, 2014

Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers

A Phase 1 interventional study of Telmisartan/Amlodipine low dose and Telmisartan/Amlodipine high dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-10.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

Study to investigate the relative bioavailability and pharmacokinetics of the fixed-dose combination tablets (telmisartan 40 mg/amlodipine 5 mg and telmisartan 80 mg/amlodipine 5 mg) in the fed condition compared with those of the same fixed-dose combination in the fasting condition in healthy Japanese male volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male volunteers without any findings and complications on the basis of a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, body temperature), 12-lead (ECGs), clinical laboratory tests
  2. Age: ≥20 and Age ≤35 years
  3. Body weight: ≥50 kg
  4. (BMI): ≥18.0 and ≤25.0 kg/m2
  5. Signed and dated written prior to admission to the trial in accordance with the Good Clinical Practice (GCP) and the local legislation

Exclusion criteria

Exclusion Criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
  2. Diseases of the central nervous system (such as epilepsy) or psychiatric or neurological disorders
  3. Chronic or relevant acute infections
  4. Any clinical relevant findings in laboratory test results deviating from normal
  5. A positive result in surface antigen (HBsAg), anti- virus (HCV) antibodies, a syphilitic test, or an (HIV) test
  6. History of surgery of the gastrointestinal tract (except appendectomy)
  7. History of relevant orthostatic hypotension, fainting spells, or blackouts
  8. Known to any component of the formulation (telmisartan and amlodipine), to any other angiotensin II receptor blockers, or to any other dihydropyridine compound
  9. Intake of drugs with a long half-life (≥24 hours) within at least 1 month or less than 10 half-lives of the respective drug before drug administration
  10. Intake of drugs which might reasonably influence the results of the trial on the basis of the knowledge at the time of protocol preparation within 7 days before drug administration
  11. Participation in another trial with an drug within 4 months or 6 half-lives of the investigational products before drug administration
  12. Smoker (≥20 cigarettes/day)
  13. Alcohol abuse (60 g or more ethanol/day: e.g., 3 middle-sized bottles of beer, 3 gous [equivalent to 540 mL] of sake)
  14. Drug abuse
  15. Blood donation (more than 100 mL within 4 weeks before drug administration)
  16. Excessive physical activities (within 1 week before drug administration)
  17. Intake of alcohol within 2 days before drug administration
  18. Inability to comply with dietary regimen of the study centre
  19. Inability to refrain from smoking during trial days
  20. Subjects judged to be inappropriate by the investigator or a sub-investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Telmisartan/Amlodipine low dose, fed

    Telmisartan low dose/Amlodipine fixed-dose combination

    Drug: Telmisartan/Amlodipine low dose · Other: Japanese meal

  • Active comparator
    Telmisartan/Amlodipine low dose, fasted

    Telmisartan low dose/Amlodipine fixed-dose combination

    Drug: Telmisartan/Amlodipine low dose

  • Experimental
    Telmisartan/Amlodipine high dose, fed

    Telmisartan high dose/Amlodipine fixed-dose combination

    Drug: Telmisartan/Amlodipine high dose · Other: Japanese meal

  • Active comparator
    Telmisartan/Amlodipine high dose, fasted

    Telmisartan high dose/Amlodipine fixed-dose combination

    Drug: Telmisartan/Amlodipine high dose

Interventions

  • DrugTelmisartan/Amlodipine low dose
  • DrugTelmisartan/Amlodipine high dose
  • OtherJapanese meal
06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)

    Time frame: up to 144 hours after drug administration

  2. Maximum measured concentration of the analyte in plasma (Cmax)

    Time frame: up to 144 hours after drug administration

Secondary outcomes

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

    Time frame: up to 144 hours after drug administration

  2. Time from dosing to the maximum concentration of the analyte in plasma (tmax)

    Time frame: up to 144 hours after drug administration

  3. Terminal rate constant of the analyte in plasma (λz)

    Time frame: up to 144 hours after drug administration

  4. Terminal half-life of the analyte in plasma (t1/2)

    Time frame: up to 144 hours after drug administration

  5. Mean residence time of the analyte in the body after po administration (MRTpo)

    Time frame: up to 144 hours after drug administration

  6. Number of subjects with adverse events

    Time frame: up to 56 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008 and a primary completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2014
First posted
Oct 10, 2014
Start
Dec 2008
Primary completionActual
Feb 2009
Last update
Oct 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02261064
Responsible party
Sponsor
First posted
Oct 10, 2014
Start date
Dec 2008
Primary completion
Feb 2009
Last update
Oct 10, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion